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ABSTRACT
Delayed platelet engraftment is a major complication of umbilical cord blood (CB) transplantation. Megakaryo-
cytes derived from CB in vitro are smaller than megakaryocytes derived from bone marrow (BM) or mobilized
peripheral blood from adults. Small megakaryocyte size may contribute to delayed platelet engraftment. To
test whether small size persists after transplantation, we measured megakaryocyte size, concentration, and
maturational stage in BM biopsy specimens obtained after transplantation in archived BM samples from
patients receiving CB (CB group, n 10) versus mobilized peripheral blood or BM transplantation (BM group,
n  9). Megakaryocytes in the postengraftment BM samples were significantly smaller in the CB group than
in the BM group (median diameter, 16.7 vs 22.0 m). There were no significant differences in megakaryocyte
concentration or maturational stage between the CB and BM groups. For the first time, we demonstrate that
the attainment of adult size in CB-derived megakaryocytes is delayed after human CB transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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Umbilical cord blood (CB) is an important stem
ell source for patients who lack other suitable donors.
owever, slower platelet engraftment is a major draw-
ack of CB transplantation [1]. Platelet engraftment
akes an average of approximately 70 days for CB
ecipients, versus 20 days for mobilized peripheral
lood cells derived from adult donors [2,3]. Posttrans-
lantation thrombocytopenia prolongs the time to
ransfusion independence and exposes patients to
omplications of transfusions [4-7].
Current theories attribute delayed engraftment af-
er CB transplantation to decreased numbers of stem
ells compared with other sources, and decreased stem
ell number clearly plays a role in delayed engraftment
8,9]. However, in children, in whom low numbers of
tem cells is less of a factor because of lower body
eight, CB transplants still have delayed engraftment
ompared with mobilized peripheral blood or bone parrow (BM) transplants from adult sources [9]. Some
ave suggested that in addition to the differences in
umbers of stem cells between the CB and mobilized
eripheral blood or BM products, intrinsic differences
n stem cells from neonatal and older donors contrib-
te to the delayed platelet engraftment after CB trans-
lantation [10-13].
Megakaryocytes of neonates are smaller and have
ower ploidy than those of adults [10-16]. Megakaryo-
ytes achieve adult size at approximately age 1 year,
imilar to the switch from fetal to adult hemoglobin
17]. Because evidence suggests that small megakaryo-
ytes produce fewer platelets than large megakaryo-
ytes [11,18], it has been hypothesized that an inability
o increase megakaryocyte size and ploidy in response
o increased platelet consumption might underlie the
redisposition of sick neonates to thrombocytopenia
19]. Applying this logic to the setting of CB trans-
lantation, and based on observations in vitro and in
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M. Ignatz et al.146ice [10-16], we hypothesized that transplanted neo-
atal stem and progenitor cells would produce smaller
egakaryocytes after hematopoietic stem cell trans-
lantation compared with the megakaryocytes pro-
uced by adult stem and progenitor cells. We tested
his hypothesis by comparing the size, megakaryocyte
oncentration, and maturational stage of megakaryo-
ytes in the BM of children who received CB trans-
lants with those who received mobilized peripheral
lood or BM transplants.
ATIENTS AND METHODS
atabase Review
All patients under age 18 years who received either
CB, BM, or mobilized peripheral stem cell trans-
lant at the University of Florida within the last 5
ears were identiﬁed from a database of stem cell
ransplant recipients. All eligible database subjects or
heir surrogates had signed an informed consent al-
owing use of their clinical information for research
urposes. This study was approved by the University
f Florida Institutional Review Board. We limited the
nalysis to patients who had achieved platelet engraft-
ent at the time of biopsy. Data collected included
iagnosis; date of transplantation; recipient age and
eight; number, type, and source of transplanted cells;
umber of transplanted CD34 cells; and dates of
ransplantation, platelet engraftment (deﬁned as plate-
et count  20,000 and rising without transfusion),
nd marrow biopsy.
egakaryocyte Analysis
Archived posttransplantation marrow biopsy sam-
les from children who underwent hematopoietic cell
ransplantation using ablative conditioning were re-
rieved and sectioned. After antigen retrieval, slides
ere immunohistochemically stained with mouse
nti-human anti-CD61 antibody (Ventana Medical
ystems, Tucson, AZ) on an automated immunos-
ainer, using a proprietary secondary antibody reagent
Nexus; Ventana Medical Systems). To be included in
his study, BM biopsy specimens had to contain rec-
gnizable megakaryocytes.
uantifying Megakaryocyte Concentration
Megakaryocyte concentration was quantiﬁed in-
ependently by 2 blinded observers using an eyepiece
eticle as described previously [13].
easuring Megakaryocyte Size
CD61 cells were measured independently using an
yepiece micrometer (Klarman Rulings Inc, Litch-
eld, NH) by 2 blinded observers. tegakaryocyte Staging
BM biopsy slides were also stained with hematox-
lin and eosin. Each megakaryocyte was then individ-
ally staged in a blinded fashion by a hematopatholo-
ist (TF) based on standard morphological criteria
20,21].
alculating Megakaryocyte Mass and Platelets
A system developed by Harker [22] was used to
alculate megakaryocyte mass for each patient. As-
uming a spherical shape, we calculated the median
egakaryocyte volume for the CB and BM trans-
lants. We multiplied this volume by the median
egakaryocyte concentration (megakaryocytes/mm2)
o calculate megakaryocyte mass (in femtoliters
fL]/mm2). We then divided this mass by a mean
latelet volume of 10 fL [23] to calculate the number
f platelets produced per mm2 of BM.
tatistical Methods
Patients who did not exhibit platelet engraftment
ere excluded from the analysis. Because of the pro-
ensity for outliers in some of the variables, nonpara-
etric methods based on ranks [24] were used. Spe-
iﬁcally, Wilcoxon’s test was used to compare 2
roups, and Spearman’s rank correlation was used to
ssess the independence of variables. For the repeated-
easures data on megakaryocyte size, the personal
eans were compared using Wilcoxon’s test. Platelet
ngraftment rates for the CB and BM groups were
ompared using Fisher’s exact test. Signiﬁcance was
et at a P value of  .05 (2-sided). A missing-at-
andom assumption was used wherever missing data
ere encountered.
ESULTS
A total of 36 patients (22 with CB and 14 with
M) had achieved platelet engraftment and were eli-
ible for this study. The time to platelet engraftment
as signiﬁcantly longer in the CB group than in the
M group (median, 47 vs 21.5 days, respectively; P 
001). A total of 19 (10 CB, 9 BM) of these patients
ad a posttransplantation BM biopsy specimen that
ontained identiﬁable megakaryocytes. Megakaryo-
yte concentration, size, and developmental stage
ere evaluated in engrafted patients who had a BM
iopsy specimen that revealed megakaryocytes. The
egakaryocyte concentration adjusted for cellularity
as similar in the 2 groups (2.28 vs 2.18 megakaryo-
ytes/mm2; P  .85).
In contrast, the megakaryocytes derived from CB
ere signiﬁcantly smaller than those derived from
dult sources (Figure 1A–C). Megakaryocytes tended
o be small and to vary little in size in patients receiv-
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Small Megakaryocytes in Umbilical Cord Blood 147ng CB transplant (Figure 1A). In contrast,
egakaryocytes tended to be larger and more variable
n size in patients receiving mobilized peripheral
lood or BM (Figure 1B). The median diameter of
egakaryocytes was signiﬁcantly smaller in the CB
roup than in the BM group (16.7 vs 22.0 m; P 
001; Figure 1C).
To determine the combined effect of size and
oncentration on platelet production, we calculated
egakaryocyte mass [25] from each patient and cal-
ulated the difference in platelet production per mm2
rom CB and adult BM assuming a mean platelet
olume of 10 fL. Patients receiving mobilized periph-
ral blood or BM produced platelets at nearly 3 times
igure 1. Representative BM megakaryocytes stained with antibo
A) Megakaryocytes in a 4-year-old patient 1 month after CB transp
egakaryocytes have a single or bilobed nucleus, typical of microm
fter mobilized peripheral blood transplantation from an adult dono
egakaryocyte diameter is signiﬁcantly smaller after CB transplant
–3 months posttransplantation. (Linemedian; box 25%–75%
M transplants.)
able 1. Megakaryocyte Mass and Platelet Production
Stem Cell Source
Megakaryocyte Concentration
(Megakaryocytes/ mm2)
M
B 2.28
obilized peripheral blood
or BM 2.18he rate as CB recipients (median, 2559 platelets/mm2
s 893 platelets/mm2; P  .069; Table 1).
Despite the size differences, there were no signif-
cant differences between CB and BM recipients in
aturity level of megakaryocytes according to mor-
hological staging (Figure 2). However, CB cells
howed a trend toward producing a lower percentage
f stage III megakaryocytes, which in normal adults
ompose the largest megakaryocyte maturational class
25% stage III megakaryocytes in the CB group vs
4% in the BM group; P  .059). In contrast, the
ercentage of stage IV mature megakaryocytes was
igher in the CB group than in the BM group (36% vs
7% stage IV megakaryocytes; P  .19). When stage
D61 followed by diaminobenzidine (megakaryocytes are brown).
on. Megakaryocytes are small and of relatively uniform size. These
yocytes [40]. (B) Megakaryocytes in a 1-year-old patient 1 month
akaryocytes are larger and have more size heterogeneity. (C) Mean
an after transplantation of hematopoietic cells from adult sources
s; bars range of individual medians; n 10 CB transplants; n 9
ryocyte Mass (Megakaryocyte
entration  Megakaryocyte
Volume, P .069)
Platelets Produced per Square
Millimeter (Assuming a Mean
Platelet Volume of 10 fL)
8933 fL/mm2 893
2dy to C
lantati
egakar
r. Meg
ation th
quartileegaka
Conc25,596 fL/mm 2559
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M. Ignatz et al.148II and IV megakaryocytes were combined, the per-
entages of “mature” megakaryocytes were similar.
ISCUSSION
The results of this study suggest that neonatal and
dult hematopoietic stem and megakaryocyte progen-
tors have intrinsic differences in their ability to pro-
uce large megakaryocytes after transplantation.
hese differences had been demonstrated in tissue
ulture [10-16] and in a mouse model of stem cell
ransplantation, [13], but this is the ﬁrst time that
mall megakaryocyte size has been reported posttrans-
lantation in human subjects. The tendency of neo-
atal stem cells to produce smaller megakaryocytes
ay contribute to the delayed platelet engraftment
fter CB transplantation.
In our previous study focusing on the differences
n megakaryocyte size after transplantation of stem
nd progenitor cells from newborn murine liver and
M, we found a rapid increase in the size of
egakaryocytes to adult size after transplantation of
eonatal cells into the adult environment. However,
hese megakaryocytes were still signiﬁcantly smaller
han those derived from BM and also had lower ploidy
evels. This suggests that both cell intrinsic and mi-
roenvironmental factors play a role in megakaryocyte
ize after transplantation.
Megakaryocyte mature along BM sinusoids,
igure 2.Hematoxylin and eosin–stained sections showing individ-
al megakaryocytes assigned a maturational stage based on size,
uclear lobulation, ratio of nucleus to cytoplasm, and degree of
ytoplasmic maturation. CB stem and progenitor cells produced a
ower percentage of stage III megakaryocytes (25% CB vs 44% BM;
 .059), which in normal adults is the largest megakaryocyte
aturational class. In contrast, CB cells produced a higher percent-
ge of stage IV mature megakaryocytes. When stage III and IV
mature) megakaryocytes are considered together, there is little
ifference between CB and BM transplants.ermed the vascular niche, which provide substances that promote megakaryocyte maturation [26]. In con-
rast to the mouse model, megakaryocyte size in-
reases more slowly after transplantation of neonatal
B cells in humans. Because the current study was
erformed in decalciﬁed samples, we were unable to
erform ploidy analysis to determine whether ploidy
iffered between the CB and BM/mobilized periph-
ral blood cohorts.
The age at which megakaryocytes achieve an adult
ean megakaryocyte diameter size in humans is un-
nown. At the time of this study, few adult patients
ad undergone CB transplantation, and no BM sam-
les from engrafted adults were available for anal-
sis. However, in our study of pediatric transplant
ecipients, megakaryocyte size was highly correlated
ith the source of the transplant, but not with the
ge of the recipient. The youngest patient to receive
mobilized peripheral blood stem cell transplant
as age 1 year and had a megakaryocyte size well
ithin the normal range for an adult (21.7 m). In
ontrast, the oldest patient to receive CB was age 10
ears and had smaller megakaryocytes than any pa-
ients who received hematopoietic stem cells from
dult sources (mean megakaryocyte diameter, 18.7
m). Sola and Rimzsa, using the same methods that
e used in the current study, demonstrated that the
ean megakaryocyte diameter was signiﬁcantly
igher in adults than in neonates (19.4 vs 15.3 m).
he median megakaryocyte diameters seen in pa-
ients after CB transplantation lie between those of
eonatal megakaryocytes and adult megakaryocytes,
uggesting that CB megakaryocyte progenitors re-
pond to environmental cues to increase megakaryo-
yte size, although this maturational response is
lunted compared with more mature stem and pro-
enitor cell sources. In contrast, and using these same
enchmarks, adult megakaryocytes 1–3 months post-
ransplantation into children were larger than
egakaryocytes in healthy adults.
Performing megakaryocyte maturational analysis
as difﬁcult on archived BM specimens. The best
ethod for analyzing ploidy level is by ﬂow cytom-
try, measuring DNA content with propidium iodide
taining, but this was not possible in ﬁxed, archived
amples. Another potential method for measuring
NA content would be through Feulgen staining
14,27], but this was not possible because the process
f decalcifying BM biopsy specimens denatures DNA.
hus, we asked a hematopathologist to morphologi-
ally assess maturational stage, based on the size of
ach megakaryocyte, using a method that incorporates
he megakaryocyte size, ratio of nucleus to cytoplasm,
nd degree of lobulation of the nucleus [20,21]. Using
his method, we found that megakaryopoiesis in the
B group resembled that of the neonate; small
egakaryocytes with mature appearing nuclei and cy-oplasm (termed “mature micromegakaryocytes”)
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Small Megakaryocytes in Umbilical Cord Blood 149ave been described in CB [19]. These small
egakaryocytes have mature-appearing cytoplasm
nd lobulated nuclei or compacted nuclei and also
ave a lower DNA content than adult megakaryo-
ytes. Prospectively collecting marrow samples and
easuring megakaryocyte ploidy would be a better
ethod for detecting differences in ploidy level after
ransplantation. In the mouse, such differences were
pparent up to 1 month posttransplantation, with
egakaryocytes derived from neonatal cells showing
ower ploidy levels than megakaryocytes derived from
dults [13].
Because children achieve adult megakaryocyte size
t age 1 year, which coincides with the time at which
emoglobin switches from fetal to adult forms, a re-
ationship between these 2 phenomena has been sug-
ested [19]. There is evidence that fetal hemoglobin is
roduced at high levels for several months in patients
eceiving CB transplants, supporting the idea that a
ell intrinsic neonatal erythroid phenotype persists for
everal months posttransplantation [28-31]. Megakaryo-
ytes and erythrocytes share common molecular path-
ays [32-36], and our results suggest that a neonatal
egakaryocytic phenotype also persists posttransplan-
ation. However, the molecular mechanisms that
ight underlie the switch from a neonatal to an adult
egakaryocyte phenotype are poorly understood.
eonatal and adult megakaryocyte progenitors re-
pond differently to the cytokine thrombopoietin in
itro, with neonatal cells predominantly proliferating,
emaining small and diploid, and adult cells endoredu-
licating, becoming polyploid, and enlarging [37,38].
t a molecular level, neonatal megakaryocyte precur-
ors had decreased expression of cyclins E and A,
hich are important regulators of endomitosis [10].
urthermore, delays in the cellular expression of an-
ther mediator of endomitosis, cyclin D3, were evi-
ent in CB-derived megakaryocytes precursors com-
ared with those from adult peripheral blood [11].
B-derived megakaryocytes have been shown to have
elayed expression of important megakaryocytic pro-
eins, such as GP IIb/IIIa [12,37], the thrombopoietin
eceptor c-mpl [37], platelet factor 4, and -thrombo-
lobulin, compared with adult-derived megakaryo-
ytes [11]. These molecular differences cause CB cells to
roduce smaller megakaryocytes and have been associ-
ted with lower levels of platelet release in vitro [11].
ecent work by our group shows that neonatal and adult
ematopoietic stem and progenitor cells proliferate and
ature very differently in response to thrombopoietin
lus adult conditioned medium derived from BM stro-
al cells [39]. Our current study suggests that these
evelopmental differences persist after CB transplanta-
ion and could play a role in delayed platelet engraft-
ent.
Although this study demonstrates that megakaryo-ytes derived from CB are smaller posttransplantationhan those derived from BM or mobilized peripheral
lood, it does not establish the relationship between
mall megakaryocyte size and time to platelet recov-
ry. This small study demonstrates the need for a
arger prospective study to evaluate the role of small
egakaryocyte size in delayed platelet engraftment.
hat study could evaluate the size of megakaryocytes
t 1-month intervals posttransplantation until adult
egakaryocyte size was reached, and perform parallel
valuations of hemoglobin electrophoresis to deter-
ine the timing of hemoglobin switching. The study
ould include ploidy analysis, megakaryocyte colony
ssays, measurements of proliferative and matura-
ional response to thrombopoietin [39], and platelet
roduction assays at each time point [11]. Such a study
lso could assess the effect of cord size, graft-versus-
ost disease, and the use of more than 1 donor on
egakaryocyte size. Finally, assays to measure activity
f molecules involved in developmental differences in
ndoreduplication, such as cyclins D3, E, A, and B,
ould be performed to determine whether and how
ong these molecular differences persist in vivo after
ransplantation [10,11].
In summary, the megakaryocytes derived from CB
re signiﬁcantly smaller than those derived from mo-
ilized peripheral blood or BM, at least when mea-
ured 1–3 months posttransplantation in pediatric pa-
ients. Smaller megakaryocytes may contribute to the
elayed platelet engraftment seen after CB transplan-
ation compared with transplants from adult hemato-
oietic stem cell sources. Understanding the molecu-
ar pathways that lead to small megakaryocyte size
ight provide new pharmacologic targets for treating
hrombocytopenia in neonates and after CB trans-
lantation.
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